Clinical Trial Detail

NCT ID NCT03696784
Title Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

nodal marginal zone lymphoma

B-cell lymphoma

primary mediastinal B-cell lymphoma

splenic marginal zone lymphoma

MALT lymphoma

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Rimiducid

Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK

Age Groups: adult senior

Additional content available in CKB BOOST